Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

Description

The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. This is a 12-week double-blind, randomized, placebo-controlled trial of NAC.

Conditions

Autism Spectrum Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder. This is a 12-week double-blind, randomized, placebo-controlled trial of NAC.

Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: A Randomized, Controlled Trial

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial

Condition
Autism Spectrum Disorder
Intervention / Treatment

-

Contacts and Locations

Palo Alto

Department of Psychiatry and Behavioral Sciences, Palo Alto, California, United States, 94304

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * children between 3 years and 12 years 11 months
  • * diagnosis of autism spectrum disorder confirmed with the Autism Diagnostic Interview- Revised and the Autism Diagnostic Observation Schedule-2, Brief Observation of Symptoms of Autism, or Childhood Autism Rating Scale
  • * at least moderate severity of restricted and repetitive behaviors defined by a Children's Yale-Brown Obsessive Compulsive Scale for Autism Spectrum Disorder score ≥ 11
  • * physical development indicative of prepubescence as defined by criteria for Tanner Stage 1
  • * if home address is within 300 miles of the primary study site, participants must pass MR safety screening (e.g., no metal in the body) and attempt baseline neuroimaging (MRI or EEG), otherwise baseline neuroimaging is not required for participation
  • * have stable medication regimens (≥ 30 days) and psychosocial treatments (≥ 60 days) prior to randomization with no anticipated changes during the trial
  • * presence of known genetic abnormalities associated with ASD (e.g. Fragile X)
  • * current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia)
  • * presence of significant medical problems
  • * the inability of at least one caregiver to speak and read English to a sufficient level
  • * participants taking glutathione agents/prodrugs
  • * history of any adverse effects to glutathione agents/prodrugs
  • * the inability to drink a sample study compound dissolved in liquid

Ages Eligible for Study

3 Years to 12 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stanford University,

John Hegarty, PhD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

2026-01-31